📣 Oncology fellows: Applications are open for the 2026–2027 FDA/ASCO Fellows’ Day Workshop! Great way to learn from FDA oncology leaders about trial design, regulatory science, and the drug/device approval process through case-based discussions and Q&A. 📌Open to oncology fellows with at least one year of completed training. 🗓️ In-person virtual options available, with up to $500 reimbursement for selected in-person participants. Apply by June 26: asco.smapply.org/ @ASCOTECAG @HemOncFellows @IMG_Oncologists

It’s #radonc away rotation season! For #medstudents and junior #residents, here are my go-to resources in radiation oncology (1/2).

With all the excitement around daraxonrasib, I needed to refresh my RAS inhibitor knowledge, so here we go:

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26

This is not simply a new pancreatic cancer drug. It is a reminder that even “undruggable” biology can become treatable with persistence. Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months. A remarkable ASCO moment. #ASCO26 @DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

Standing ovation for a ***breakthrough*** in #pancreaticcancer 🥹🥹🥹 #RASolute today presented at #ASCO26: Daraxonrasib DOUBLES the median overall survival in metastatic pancreatic cancer w/ w/o RAS (mOS 13.2 mo vs. 6.6 mo) A HUGE advance in one of the most lethal cancers 💜

A big moment for the sarcoma community at #ASCO26.

🤩SARCOMA AT PLENARY!🎗️ 🔹 SARC041 provides the first randomized validation of CDK4 inhibition in DDLPS 📈 mPFS: 9.7 vs 1.5 mo (HR 0.39, p<0.001) — >6× improvement 🎯 ORR: 9.3% vs 0% ⏳ OS trend favors abemaciclib (HR 0.55) 🔄 Crossover activity confirmed (mPFS 3.4 mo) #ASCO26

🚨 first up #PROTEUS Phase 3 Adding peri-op apalutamide to ADT significantly improves outcomes for high-risk localized prostate cancer undergoing surgery: 🔹 pCR/MRD: 8.9% vs 1.0% (10x OR!) 🔹 5-y MFS: 78.2% vs 73.5% (HR 0.80) ⚠️ 8% more gr3/4 tx AEs #ProstateCancer #ASCO26

Full house for plenary! #ASCO26 🌟 LIBRETTO-432: adjuvant selpercatinib in stage IB-IIIA RET NSCLC 🌟 PROTEUS: apalutamide peri-op tx in PCa 🌟 RASolute 302: RAS inhibition in pancreatic cancer. 🌟 HARMONi-6: ivonescimab for NSCLC 🌟 SARC041: abemaciclib in liposarcoma

Amazing work @GarradEvan presenting our work assessing AI use in heme/onc fellowship, simultaneously published @JCOOP_ASCO ▶️stay tuned on our HOF curriculum ascopubs.org/doi/10.1200/OP-… @TwoOncDocs @TheFellowOnCall @christinemphmd @DrJessDeLaune @DeepaRangachari @inas_md #ASCO26

PD breakfast #ASCO26 w/ our amazing LDP ESP crew🥰 & impt info on signals for the match🏅 ✅for applicants: interviews jump from 9.5% to 25.5% w/ Silver and 52.3% w/ Gold ⚠️if you don't signal a program, the interview rate drops below 5% ▶️ tips on signals for programs

At #ASCO2026 representing Ohio and advocating for a stronger future in cancer care. The conversations we have here can shape the future of cancer care for years to come. #ASCO #CancerCare #Oncology #Advocacy #Ohio #HealthPolicy

Our wonderful MSL & colleagues made their yearly list! For your exhibit wanderings 😋🍩 #ASCO26 @ASCO

Great connecting with @SamArmstrongMD, leader of the @IndianaUniv #Sarcoma Team and mastermind of @TwoOncDocs #ASCO2026

My fav ASCO D2 highlight so far. Cheesing because we met half of @TwoOncDocs @ASCO @asco2026

PODCAST-HOF trial featuring @TheFellowOnCall and @TwoOncDocs and published in @JCO_ASCO-OP being highlighted as one of the biggest med ed research studies of the past year to know at the #ASCO26 Medical Education Committee on Practice event! 🎉

Fueling for day 2 ☕️ this AM: Bladder/RCC - rad-IO in TMT, QoL from #KN905 & adj pembro Exhibits open!🍭 📝 Women Networking Center 11-11:45 - mentor-led discussion how to evaluate contract terms, articulate professional value & agreement you deserve #ASCO26 #Womeninmedicine